Merck hasn't said a peep about yesterdays Ridaforolimus results. I'm not even sure they put out a PR or Joint-PR on the subject.
Any thoughts on why?
I don't see anything either. I think that's a very fair question to ask. Why wouldn't you put out a PR at least, if not hold a CC, detailing Phase 3 top-line results for a drug you're so heavily involved with?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.